{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:09:13Z","timestamp":1773101353808,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neurol.2025.12.004","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:40:02Z","timestamp":1768596002000},"page":"193-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-interval dosing of anti-CD20 therapy: Toward affordable treatment for multiple sclerosis"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3119-8203","authenticated-orcid":false,"given":"C.","family":"Boutiere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Saunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5395-9963","authenticated-orcid":false,"given":"A.","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-0563","authenticated-orcid":false,"given":"M.","family":"Perriguey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Demortiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hilezian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maarouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roudot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurol.2025.12.004_bib0035","doi-asserted-by":"crossref","first-page":"e200056","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.neurol.2025.12.004_bib0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.neurol.2025.12.004_bib0045","doi-asserted-by":"crossref","first-page":"e00554","DOI":"10.1016\/j.neurot.2025.e00554","article-title":"Extended-interval dosing of rituximab\/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis","volume":"22","author":"Rigollet","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.neurol.2025.12.004_bib0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurol.2025.12.004_bib0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","article-title":"Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab","volume":"87","author":"de Flon","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2025.12.004_bib0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:20:10Z","timestamp":1773062410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0035378726000019"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.12.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-interval dosing of anti-CD20 therapy: Toward affordable treatment for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}